Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2009 pubmed 33 citations

Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.

Venkova. Kalina K; Mann. William W; Nelson. Richard R; Greenwood-Van Meerveld. Beverley B

Key Findings

  • A single intravenous dose of ipamorelin (1 mg/kg) reduced the time to the first bowel movement after surgery.
  • Repeated dosing (0.1–1 mg/kg, four times daily for two days) increased cumulative fecal output, food intake, and body‑weight gain.
  • The effects were observed in a rodent model of postoperative ileus, using intravenous administration.

Practical Outcomes

  • For self‑experimenters, ipamorelin may help stimulate appetite and promote weight gain if given repeatedly, but the evidence comes from rats after abdominal surgery and uses IV delivery. Human dosing routes (e.g., subcutaneous) and safety are not addressed, so any protocol would be speculative and should be approached with caution.

Summary

In rats that had gut surgery, a single IV dose of ipamorelin (a ghrelin‑like peptide) made them poop sooner, but didn’t change how much they ate or gained weight. Giving the peptide repeatedly (four times a day for two days) did raise food intake, stool output, and body‑weight gain. The study shows that ipamorelin can speed up gut movement and boost appetite when used multiple times, at least in this animal model.

Abstract

Ghrelin and ghrelin mimetics stimulate appetite and enhance gastric motility. The present study investigates whether ipamorelin, a selective growth hormone secretagogue and agonist of the ghrelin receptor, would accelerate gastrointestinal transit and ameliorate the symptoms in a rodent model of postoperative ileus (POI). Fasted male rats were subjected to laparotomy and intestinal manipulation. At the end of surgery, a dye marker was infused in the proximal colon to evaluate postsurgical colonic transit time, which was the time to the first bowel movement. In addition, fecal pellet output, food intake, and body weight were monitored regularly for 48 h. Ipamorelin (0.01-1 mg/kg), growth hormone-releasing peptide (GHRP)-6 (20 microg/kg), or vehicle (saline) were administered via intravenous bolus infusion after a single dosing or a 2-day repetitive dosing regimen (four doses a day at 3-h intervals). Compared with the vehicle, a single dose of ipamorelin (1 mg/kg) or GHRP-6 (20 microg/kg) decreased the time to the first bowel movement but had no effect on cumulative fecal output, food intake, or body weight gain measured 48 h after the surgery. In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in patients with POI.

Study Information

Provider

pubmed

Year

2009

Date

2009-03-16T00:00:00.000Z

DOI

10.1124/jpet.108.149211

Citations

33

References

42